Trinity Biotech (TRIB) Long-Term Debt Repayments (2009 - 2022)
Trinity Biotech recorded quarterly Long-Term Debt Repayments of -$23000.0 in Q4 2022, up 88.14% quarter-over-quarter from -$194000.0 in Q4 2010.
Trinity Biotech's Long-Term Debt Repayments history runs 3 years deep, the most recent figure standing at -$23000.0 for Q4 2022.
- In Q4 2022, Long-Term Debt Repayments changed N/A year-over-year to -$23000.0; the TTM figure through Dec 2022 stood at -$27.3 million (changed N/A YoY), while the FY2022 annual figure was -$23000.0, changed N/A from the prior year.
- Long-Term Debt Repayments came in at -$23000.0 for Q4 2022 at Trinity Biotech, up from -$194000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of -$23000.0 in Q4 2022 to a low of -$23000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.42 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 1.00 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Trinity Biotech | 28,000.00 | -5.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -23,000.00 |
| Dec 31, 2022 | -23,000.00 |
| Dec 31, 2010 | -194,000.00 |
| Dec 31, 2010 | -194,000.00 |
| Jun 30, 2010 | -27.12 Mn |
| Jun 30, 2010 | -27.12 Mn |
| Mar 31, 2010 | -2.44 Mn |
| Mar 31, 2010 | -2.44 Mn |
| Dec 31, 2009 | -39,000.00 |
| Dec 31, 2009 | -39,000.00 |
| Sep 30, 2009 | -3.22 Mn |
| Sep 30, 2009 | -3.22 Mn |
| Mar 31, 2009 | -2.15 Mn |
| Mar 31, 2009 | -2.15 Mn |